Abstract 13226: Impact of Esomeprazole on Platelet Reactivity and Clinical Outcome According to CYP2C19 Genotype in Coronary Heart Disease Patients during Dual Antiplatelet Therapy
Background: Several studies have indicated that concomitant use of clopidogrel and a proton pump inhibitor (PPI) is associated with reduced antiplatelet efficacy of clopidogrel, and increased adverse clinical outcomes after stent placement in patients with ACS. The antiplatelet efficacy of clopidogrel depends on CYP2C19 polymorphism or the co-administration of some kind of PPI. The aim of this study was to investigate the effect of CYP2C19 polymorphism and co-therapy with esomeprazole on the antiplatelet efficacy of clopidogrel.
Methods: CYP2C19 genotype and the residual platelet reactivity (RPR) were measured in 361 coronary heart disease patients (male, 73.4%; mean age, 69 years), and the risk of cardiovascular events over a 30-day follow-up was assessed to evaluate the impact of co-administration of esomeprazole during dual antiplatelet therapy with aspirin and clopidogrel.
Results: The values of RPR did not differ between esomeprazole and non-esomeprazole groups (4389±1112 versus 4079±1355 AU·min, P=0.103). RPR value was higher in intermediate metabolizers (IM) than in extensive metabolizers (EM) (4089±1252 versus 3697±1215 AU·min P=0.012) and, similarly, higher in poor metabolizers (PM) than in IM (4884±1027 versus 4089±1252 AU·min, P<0.001). There were no differences in RPR between esomeprazole and non-esomeprazole groups according to CYP2C19 genotype (EM, 3954±1192 versus 3645±1220 AU·min, P=0.361; IM, 4401±1063 versus 4051±1271 AU·min, P=0.293; PM, 4917±669 versus 4876±1099 AU·min, P=0.907, respectively). There was also no difference in clinical outcomes between esomeprazole and non-esomeprazole groups in the one-month follow-up (0% versus 0.92%, P=0.487).
Conclusions: These results suggest that concomitant use of esomeprazole with clopidogrel is not associated with reduced antiplatelet efficacy of clopidogrel or increased risk of cardiovascular events, irrespective of CYP2C19 genotype.
Author Disclosures: S. Hokimoto: None. K. Kaikita: None. K. Nakaawa: None. H. Ogawa: Other Research Support; Modest; AstraZeneca, Astellas, Boehringer lngelheim, Bristol-Myers Squibb, Daiichi Sankyo, Dainippon Sumitomo Pharma, Kowa, MSD, Novartis, Pfizer, Sanofi, Takeda. Other Research Support; Significant; Bayer, Chugai, Otsuka. Honoraria; Modest; AstraZeneca, Bayer, Pfizer, Sanofi, Takeda. Honoraria; Significant; Daiichi Sankyo, MSD.
- © 2014 by American Heart Association, Inc.